Dawn Christine Maroney Sells 228,152 Shares of Alignment Healthcare (NASDAQ:ALHC) Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) President Dawn Christine Maroney sold 228,152 shares of the stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $21.33, for a total transaction of $4,866,482.16. Following the transaction, the president owned 1,057,015 shares of the company’s stock, valued at approximately $22,546,129.95. This represents a 17.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Dawn Christine Maroney also recently made the following trade(s):

• On Friday, January 2nd, Dawn Christine Maroney sold 100,000 shares of Alignment Healthcare stock. The stock was sold at an average price of $20.03, for a total value of $2,003,000.00.
• On Monday, December 29th, Dawn Christine Maroney sold 282,070 shares of Alignment Healthcare stock. The stock was sold at an average price of $18.74, for a total value of $5,285,991.80.
• On Monday, December 15th, Dawn Christine Maroney sold 113,319 shares of Alignment Healthcare stock. The shares were sold at an average price of $20.01, for a total value of $2,267,513.19.
• On Friday, December 12th, Dawn Christine Maroney sold 16,681 shares of Alignment Healthcare stock. The shares were sold at an average price of $20.02, for a total transaction of $333,953.62.

Alignment Healthcare Price Performance

Shares of ALHC opened at $20.93 on Thursday. The company has a current ratio of 1.61, a quick ratio of 1.61 and a debt-to-equity ratio of 1.99. The company’s fifty day simple moving average is $18.55 and its 200 day simple moving average is $16.46. Alignment Healthcare, Inc. has a 1-year low of $11.48 and a 1-year high of $21.65. The company has a market cap of $4.19 billion, a price-to-earnings ratio of -174.42, a PEG ratio of 6.12 and a beta of 1.16.

Alignment Healthcare (NASDAQ:ALHC) last announced its quarterly earnings data on Thursday, October 30th. The company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.03. The company had revenue of $993.70 million during the quarter, compared to the consensus estimate of $980.90 million. Alignment Healthcare had a negative net margin of 0.57% and a negative return on equity of 16.23%. The company’s quarterly revenue was up 43.5% on a year-over-year basis. During the same quarter last year, the firm posted ($0.14) EPS. On average, research analysts forecast that Alignment Healthcare, Inc. will post -0.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Larson Financial Group LLC bought a new stake in shares of Alignment Healthcare in the third quarter valued at about $33,000. SBI Securities Co. Ltd. raised its stake in Alignment Healthcare by 4,868.9% in the 2nd quarter. SBI Securities Co. Ltd. now owns 3,031 shares of the company’s stock worth $42,000 after purchasing an additional 2,970 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Alignment Healthcare by 83.8% in the 4th quarter. GAMMA Investing LLC now owns 2,165 shares of the company’s stock valued at $43,000 after purchasing an additional 987 shares during the period. KBC Group NV acquired a new position in shares of Alignment Healthcare during the 2nd quarter worth approximately $44,000. Finally, Signaturefd LLC grew its position in shares of Alignment Healthcare by 142.6% during the 2nd quarter. Signaturefd LLC now owns 3,768 shares of the company’s stock worth $53,000 after purchasing an additional 2,215 shares in the last quarter. Institutional investors own 86.19% of the company’s stock.

Wall Street Analysts Forecast Growth

ALHC has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alignment Healthcare in a research report on Wednesday, October 8th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $22.00 price objective on shares of Alignment Healthcare in a research report on Monday, November 3rd. Barclays upped their price objective on shares of Alignment Healthcare from $13.00 to $18.00 and gave the company an “equal weight” rating in a report on Friday, October 31st. Piper Sandler raised their target price on shares of Alignment Healthcare from $20.00 to $30.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, JPMorgan Chase & Co. lifted their target price on shares of Alignment Healthcare from $20.00 to $23.00 and gave the stock an “overweight” rating in a report on Wednesday, December 17th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Alignment Healthcare presently has an average rating of “Moderate Buy” and a consensus price target of $21.25.

Alignment Healthcare News Summary

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Recent quarterly results showed revenue strength and an EPS beat (Qtr revenue ≈ $993.7M, +43.5% YoY; EPS $0.02 vs. consensus -$0.01), which supports growth expectations and helps explain upside interest from investors. Read More.
• Neutral Sentiment: Analyst coverage is active — some firms have raised price targets (consensus ~$21.25) while others remain neutral; Benzinga’s analyst roundup could amplify moves if any major upgrades or target changes are published. Read More.
• Negative Sentiment: Large insider sales were disclosed this week, including significant dispositions by President Dawn Maroney (100,000 shares sold ~Jan 2 and a separate filing showing 228,152 shares sold) and other executives (Christopher Joyce, Hyong Kim). Investors often interpret material executive selling near highs as profit-taking or reduced insider conviction, which can pressure the stock. Read More. • Read More.
• Negative Sentiment: A recent valuation-focused piece raises the question of whether current valuations already price in expected growth, signalling potential overpaying risk for new buyers if execution slows or multiples compress. That stokes caution even with solid top-line growth. Read More.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.